The anti-clot treatment scale (ACTS): validation of the translated Arabic version among patients undergoing warfarin therapy in Saudi Arabia

Table 1 Feasibility of the ACTS Burdens and Benefits scales, N = 136

	Items with missing data (%)	Possible range (midpoint)	Actual score range	Distribution (%^a)	Mean score ± SD	Floor/ceiling effects (%/%)^b	Skewness
Burden items
Item 1	0	1–5 (3)	1–5	100	3.51 ± 1.29	10/29	−0.454
Item 2	0	1–5 (3)	1–5	100	3.70 ± 1.30	7/39	−0.582
Item 3	0	1–5 (3)	1–5	100	3.62 ± 1.30	8/34	−0.550
Item 4	0	1–5 (3)	1–5	100	3.71 ± 1.37	9/42	−0.636
Item 5	0	1–5 (3)	1–5	100	3.52 ± 1.25	9/27	−0.467
Item 6	0	1–5 (3)	1–5	100	3.71 ± 1.19	7/33	−0.643
Item 7	0	1–5 (3)	1–5	100	3.46 ± 1.21	9/24	−0.421
Item 8	0	1–5 (3)	1–5	100	3.52 ± 1.41	12/38	−0.425
Item 9	0	1–5 (3)	1–5	100	3.88 ± 1.30	7/47	−0.862
Item 10	0	1–5 (3)	1–5	100	3.64 ± 1.28	8/34	− 0.585
Item 11	0	1–5 (3)	1–5	100	3.93 ± 1.18	4/45	−0.807
Item 12	0	1–5 (3)	1–5	100	3.82 ± 1.25	6/43	−0.707
ACTS Burdens scale	0	12–60 (36)	15–60	94	44.01 ± 9.89	0/2	−0.556
Benefits items
Item 14	0	1–5 (3)	1–5	100	4.14 ± 0.93	1/43	−0.903
Item 15	0	1–5 (3)	1–5	100	3.91 ± 0.94	2/31	−0.586
Item 16	0	1–5 (3)	1–5	100	3.87 ± 1.04	4/33	−0.737
ACTS Benefit scale	0	3–15 (9)	4–15	92	11.91 ± 2.39	0/21	−0.556

^aCalculated as the actual range divided by possible range multiplied by 100
^bCalculated as the percentage of people scoring either 12 (floor) or 60 (ceiling) on the ACTS Burdens scale or 3 (floor) or 15 (ceiling) on the ACTS Benefits scale
Abbreviaton: SD standard deviation

ISSN: 1477-7525